Latest News

Phase 2b results demonstrate significant and sustained efficacy in treating human papilloma virus and precancerous lesions of the cervix.

Cevira® was recently presented in the Nolato Magazine no 25. Oct 2014.

The results of the Cevira Phase 2b were presented 10.10.2014 at the annual German gynecology meeting (DGGG) in Munich, one of the key gynecology conferences in Europe with nearly 2000 participants.

Cysview® improves detection of Non-Muscle Invasive Bladder Cancer (NMIBC) beyond that achieved with current standard of care.

Oslo, Norway, 10th July 2014: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, is pleased to note that updated expert recommendations on the clinical and cost effectiveness of Hexvix have been published in European Urology.

The Swedish Medical Product Agency (MPA) together with The Public Health Authorities with updated recommendations for acne treatment.

Bill makes most up-to-date cancer treatment available to patients; requires fair payment policy for hospitals

New Market Opportunity Analysis and forecast to 2018 prepared by GlobalData highlights Visonac photodynamic therapy for acne as one of the anticipated new product launches that will drive the expansion within the acne market.

Bladder Cancer Advocacy Network urging Congress to enact legislation to secure access to Blue Light Cystoscopy with Cysview

German Institute for Quality and Efficacy in Health Care (IQWiG) confirms benefit of human papilloma-virus (HPV) testing for preventing cervical cancer.

Oslo, Norway, 7 May 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the first quarter 2014.

FDA approves first HPV test for primary cervical cancer screening

FDA advisory committee recommends Roche's HPV test for primary screening of cervical cancer.

Oslo, Norway, 27 February 2014: Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announces its results for the fourth quarter and full year of 2013.